Anna Podolanczuk, M.D., M.S.

Anna Podolanczuk, M.D., M.S., discusses the key unmet needs in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), and how artificial intelligence (AI) could play a transformative role in enabling earlier detection of these diseases in the future.

Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these diseases from other respiratory conditions, as well as the role of biopsy and the histopathological features commonly seen in these diseases.

Anna Podolanczuk, M.D., M.S., discusses how the differential diagnosis for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is approached, the importance of early diagnosis and why these diseases are often misdiagnosed.

Anna Podolanczuk, M.D., M.S., discusses how key epidemiological trends in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including changes in incidence and prevalence, contribute to the growing economic burden that patients with these conditions face.

Anna Podolanczuk, M.D., M.S., discusses how the mortality rates for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are impacted by comorbidities, including the role of autoimmune diseases in the pathophysiology of these conditions.

Anna Podolanczuk, M.D., M.S., discusses how different types of interstitial lung diseases and their main risk factors contribute to the development of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), as well as how these diseases present with common symptoms and progress over time.